戻る
Editas Medicine Inc (EDIT)価格
EDIT 株価推移チャート
EDIT 収入
Editas Medicine Inc
$1.82
9.3%
$0.15
終値： Feb 06, 16:00:00 GMT-5
$1.81
-0.54%
$-0.01
アフターマーケット：Feb 06, 20:00:00 GMT-5
主要データ
前終値
$1.66
始値
$1.78
当日レンジ
$1.73 - $1.84
52週レンジ
$0.91 - $4.53
取引高
1.9M
平均取引高
1.7M
1株当たり利益(TTM)
-2.38
配当利回り
--
時価総額
$176.6M
EDITとは何ですか？
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.